Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar? [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
This compares to the stock's 9.6% gain over the past four weeks. The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding Filspari's (sparsentan) potential to earn increasing revenues for the company. The drug, approved for treating IgA nephropathy, a form of kidney disease, has been witnessing solid uptake in the market. Travere recorded sales of $40 million in first-quarter 2024, up 65% year-over-year, primarily driven by an increase in sales from the ongoing commercial launch of Filspari. The company is also looking to expand the drug's indication to include another type of kidney disease. Travere's commercial portfolio also comprises Thiola EC/Thiola which is approved for cystinuria. Moreover, Travere's clinical-stage pipeline has another late-stage candidate, being developed for homocystinuria, which is progressing well. This drug developer is expected to post quarterly loss of $0.84 per share in its upcoming report, which repre
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago [Yahoo! Finance]Yahoo! Finance
- American Kidney Fund Convenes Rare Kidney Disease Action Network to Advocate for Policies and Regulations that Help Patients with Rare Causes of Kidney Disease [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Why Is Ligand (LGND) Up 4% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Promising Findings on Kidney Function Preservation in IgA Nephropathy Patients at National Kidney Foundation Spring Clinical Meetings [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 5/6/24 - Miss
TVTX
Sec Filings
- 6/14/24 - Form S-8
- 5/13/24 - Form 8-K
- 5/10/24 - Form 4
- TVTX's page on the SEC website